Baidu
map

NEJM:预防性PCI可降低STEMI患者的心血管不良事件风险(PRAMI研究)

2013-09-03 MedSci MedSci原创

图1. 主要终点的Kaplan–Meier曲线 关键要点: 预防性PCI指在有显著狭窄但尚未梗死的动脉血管进行PCI治疗PRAMI研究旨在评估预防性PCI对STEMI患者的疗效PRAMI研究中,预防性PCI治疗可降低STEMI患者心源性、非致命性心梗和难治性心绞痛引发的死亡风险。 对于急性ST段抬高型心肌梗死(STEMI)患者,临床医生对发生梗死的病变血管行经皮冠状动脉介入治疗(


图1. 主要终点的Kaplan–Meier曲线

关键要点:


  • 预防性PCI指在有显著狭窄但尚未梗死的动脉血管进行PCI治疗
  • PRAMI研究旨在评估预防性PCI对STEMI患者的疗效
  • PRAMI研究中,预防性PCI治疗可降低STEMI患者心源性、非致命性心梗和难治性心绞痛引发的死亡风险。
对于急性ST段抬高型心肌梗死(STEMI)患者,临床医生对发生梗死的病变血管行经皮冠状动脉介入治疗(PCI)可改善临床预后,但PCI术在显著狭窄但尚未梗死的冠状动脉治疗(预防性PCI术)
中的意义尚不清楚。为此,研究人员进行了PRAMI这一研究,研究结果发表在2013年9月1日NEJM杂志上。

2008年至2013年间,研究人员在英国5个医学中心招募了465名正接受梗死动脉PCI治疗的STEMI患者,其中3名患者伴有左束支传导阻滞。研究人员将受试者随机分配为两组,一组接受预防性PCI治疗,一组未接受预防性PCI治疗。只有患者出现难治性心绞痛并伴缺血证据时,才建议对患者进行后续PCI治疗心绞痛。研究主要终点为心源性、非致命性心肌梗死或难治性心绞痛引起的死亡。

2013年1月,数据和安全监督委员会认定研究结果可信,并建议提前终止试验。受试者平均随访23个月后,预防性PCI治疗组和未接受预防性PCI治疗组分别有21名(9%)和53名(23%)患者发生主要终点事件,其中主要终点的三个组成成分心源性死亡、非致命性心肌梗死致死和难治性心绞痛致死的危险比分别为0.34、0.32和0.35。

本次研究发现,对于接受梗死动脉PCI术的ST段抬高型心梗和多血管冠状动脉疾病患者而言,预防性PCI治疗可显著降低心血管不良事件风险。

原始出处:
Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Oldroyd KG; the PRAMI Investigators.Randomized Trial of Preventive Angioplasty in Myocardial Infarction. N Engl J Med. 2013 Sep 1.
全文下载Randomized Trial of Preventive Angioplasty in Myocardial Infarction.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034729, encodeId=3f362034e29d8, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Dec 15 00:31:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007378, encodeId=72a8200e3787c, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Jun 17 11:31:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936682, encodeId=467919366829f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Mar 19 16:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481803, encodeId=b61f148180302, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511552, encodeId=09d51511552e1, content=<a href='/topic/show?id=20cc51e3241' target=_blank style='color:#2F92EE;'>#心血管不良事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51732, encryptionId=20cc51e3241, topicName=心血管不良事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766910366053, createdName=ms3117646317107274, createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034729, encodeId=3f362034e29d8, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Dec 15 00:31:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007378, encodeId=72a8200e3787c, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Jun 17 11:31:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936682, encodeId=467919366829f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Mar 19 16:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481803, encodeId=b61f148180302, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511552, encodeId=09d51511552e1, content=<a href='/topic/show?id=20cc51e3241' target=_blank style='color:#2F92EE;'>#心血管不良事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51732, encryptionId=20cc51e3241, topicName=心血管不良事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766910366053, createdName=ms3117646317107274, createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034729, encodeId=3f362034e29d8, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Dec 15 00:31:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007378, encodeId=72a8200e3787c, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Jun 17 11:31:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936682, encodeId=467919366829f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Mar 19 16:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481803, encodeId=b61f148180302, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511552, encodeId=09d51511552e1, content=<a href='/topic/show?id=20cc51e3241' target=_blank style='color:#2F92EE;'>#心血管不良事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51732, encryptionId=20cc51e3241, topicName=心血管不良事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766910366053, createdName=ms3117646317107274, createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034729, encodeId=3f362034e29d8, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Dec 15 00:31:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007378, encodeId=72a8200e3787c, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Jun 17 11:31:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936682, encodeId=467919366829f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Mar 19 16:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481803, encodeId=b61f148180302, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511552, encodeId=09d51511552e1, content=<a href='/topic/show?id=20cc51e3241' target=_blank style='color:#2F92EE;'>#心血管不良事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51732, encryptionId=20cc51e3241, topicName=心血管不良事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766910366053, createdName=ms3117646317107274, createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034729, encodeId=3f362034e29d8, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sun Dec 15 00:31:00 CST 2013, time=2013-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007378, encodeId=72a8200e3787c, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Jun 17 11:31:00 CST 2014, time=2014-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936682, encodeId=467919366829f, content=<a href='/topic/show?id=74bd16e850c' target=_blank style='color:#2F92EE;'>#STEMI患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16785, encryptionId=74bd16e850c, topicName=STEMI患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Mar 19 16:31:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481803, encodeId=b61f148180302, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511552, encodeId=09d51511552e1, content=<a href='/topic/show?id=20cc51e3241' target=_blank style='color:#2F92EE;'>#心血管不良事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51732, encryptionId=20cc51e3241, topicName=心血管不良事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=766910366053, createdName=ms3117646317107274, createdTime=Thu Sep 05 13:31:00 CST 2013, time=2013-09-05, status=1, ipAttribution=)]

相关资讯

北京STEMI病人PCI使用率较其他国家低

  2012年世界心脏病学大会(4月18~21日,阿联酋迪拜)上公布的我国北京市心肺血管疾病研究所、北京安贞医院的研究人员开展的一项研究显示:与其他国家相比,在中国经济最发达的地区——北京,ST段抬高型急性心肌梗死(STEMI)病人的经皮冠状动脉介入术(PCI)使用率仍较低。STEMI病人的医疗质量存在很大差距,尤其是北京的二级医院。   虽然指南推荐用PCI治疗S

韩雅玲:STEMI患者早期再灌注策略的优化

  心肌梗死是心血管疾病中的危急情况,致死及致残率高。实施有效的早期再灌注治疗,挽救濒死的心肌是急性ST 段抬高型心肌梗死(STEMI)治疗的关键环节。心肌梗死发生后2 h 尤其是1 h 以内是再灌注的“黄金时间”,如果能在这段时间内实现心肌水平的再灌注,挽救的心肌数量是最多的,所以2 h 内再灌注是STEMI 治疗追求的理想目标。在“黄金时间”每治疗1000 例患者,可以挽

STEMI病人PCI术前应用山莨菪碱或预防造影剂肾病

  我国河北医科大学附属第二医院研究人员在2012年世界心脏病学大会上报告的一项研究显示:ST段抬高型心肌梗死(STEMI)病人直接经皮冠状动脉介入(PCI)术前静脉输注山莨菪碱,有可能预防造影剂肾病(CIN)的发生。   CIN是PCI术后最严重的并发症之一。接受直接PCI的急性心肌梗死病人发生CIN的风险较大。山莨菪碱是从中草药中提取的一种生物碱,广泛用于治疗感染性休克、急性肾小球肾炎和糖尿

ACC 2013:STEMI后应在症状指导下行非罪犯血管血运重建

 STEMI后应在症状指导下行非罪犯血管血运重建   David Joel Maron  美国范德比尔特大学医学院   David Joel Maron  范德比尔特大学胸痛中心主任,Dayani健康与保健中心医疗主任,急救医学教授。主要临床兴趣为预防心脏病学,脂质紊乱和缺血性心脏病。   40%~65% STEMI患者伴MVD,比伴单支血管病变患者预后差。2011 A

EHJ:直接PCI术中血栓抽吸可降低STEMI患者死亡率

     9月17日《欧洲心脏杂志》(Eur Heart J)发表一项针对真实世界的非选择性ST段抬高心肌梗死患者(STEMI)的研究,结果表明尤其对于总缺血时间较短的患者,直接经皮冠脉介入治疗(PPCI)术中行血栓抽吸可显著降低死亡率。  研究者于2008-2011年间共搜集2567例接受PPCI治疗的STEMI 患者。采用Cox比例风险模型和多元逻辑回归分析校正

CCI:达比加群并不能减少STEMI后行直接PCI术患者的梗死面积

HIRIZON-AMI研究是一项大型、前瞻性、随机的急性心肌梗死患者接受再血管化治疗和支架的预后研究。在这项研究中比较了在ST段抬高性心肌梗死患者在直接PCI术后,使用直接凝血酶原抑制剂达比加群与普通肝素加糖蛋白IIb/IIIa受体拮抗剂对全因死亡率和心血管死亡的影响。由于减少大出血事件方面的效应,达比加群组的死亡率较低。但对STEMI患者而言,心肌梗死面积是除了大出血之外的一项影响预后的重要因素

Baidu
map
Baidu
map
Baidu
map